HENLIUS (02696) surged over 8% in early trading, reaching a high of HK$89 and setting a new historical record. As of press time, the stock was up 5.31% to HK$86.2 with a trading volume of HK$73.65 million.

On the news front, HENLIUS announced that the first prescriptions for its innovative small-molecule CDK4/6 inhibitor Vorvicimib (Vorvicimib Citrate Capsules) have been issued by more than ten hospitals across the country in recent days. These hospitals include Fudan University Shanghai Cancer Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Zhejiang University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Shandong Cancer Hospital, Shanghai Tenth People's Hospital, Nanjing Drum Tower Hospital, and The Affiliated Hospital of Qingdao University.

According to reports, Vorvicimib in combination with fulvestrant is indicated for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have experienced disease progression following prior endocrine therapy.

HENLIUS stated that this drug possesses independent intellectual property rights owned by Jinzhou Aohong Pharmaceutical, a member company of Fosun Pharma, while HENLIUS is responsible for its commercial promotion in China.